Breaking News Instant updates and real-time market news.

VRX

Valeant

$8.88

-0.14 (-1.55%)

07:33
04/21/17
04/21
07:33
04/21/17
07:33

Valeant to list SILIQ injection at $3,500 per month

Valeant announced that following the evaluation and approval of its Patient Access and Pricing Committee, the company has decided to list SILIQ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the company's patient access program to further offer financial support and access to patients. SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of SILIQ are expected to commence in the U.S. during the second half of 2017.

  • 02

    May

  • 09

    May

  • 06

    Jun

  • 24

    Aug

VRX Valeant
$8.88

-0.14 (-1.55%)

03/18/17
WELS
03/18/17
NO CHANGE
WELS
Underperform
Valeant management positive on new FDA guidelines, says Wells Fargo
Wells Fargo analyst David Maris said in a research note late Friday that Valeant Pharmaceuticals views the FDA's new guidance for generic Xifaxan as a positive. Management believes the guidelines may delay generics which may not have conducted their studies to be compliant with the new guidance, Maris told investors in a research note. The analyst earlier in the day Friday told investors that he views the FDA's guidance as a "game changing development that makes it much easier for generics to show bioequivalence." Maris called the news a "new significant negative" for Valeant. He says his initial read is not changed by Valeant management's view, but added that he will review the feedback with outside consultants and other industry sources to gain a broader perspective. Maris has an Underperform rating on Valeant, his firm's equivalent of a sell. Shares of Valeant closed yesterday down 17c to $11.03.
04/05/17
WELS
04/05/17
NO CHANGE
WELS
Underperform
Valeant may break $10 amid lukewarm iNova interest, Wells Fargo says
According to the Australian Business Review, Valeant Pharmaceuticals' iNova unit has received lukewarm interest with bids coming in under $1B, Wells Fargo analyst David Maris tells investors in a research note. This is another disappointment as some investors had expected $1B in proceeds for the unit, the analyst adds. What was promised to be $8B worth of asset sales has thus far only been approximately $2B, Maris points out. He is not surprised by today's report, however, noting Valeant's recent debt refinancing was a sign that "near term asset sales of significant value are not at hand." Maris adds that he wouldn't be surprised if Valeant shares break the "psychological price point of $10" in the near-term since management is yet to demonstrate a turnaround. The analyst keeps an Underperform rating on the shares. The drugmaker in early trading is down 4c to $10.13.
04/11/17
PIPR
04/11/17
NO CHANGE
Target $10
PIPR
Underweight
Piper dermatologist survey shows Siliq won't change Valeant's fortunes
After surveying 27 medical dermatologists, Piper Jaffray analyst David Amsellem does not believe Siliq can change the fortunes of Valeant Pharmaceuticals' dermatology segment. Siliq is likely to lag "far behind" other IL-17A antagonists in terms of adoption for treatments of moderate-to-severe plaque psoriasis, Amsellem tells investors in a research note. The analyst thinks Valeant's "sanguine commentary about the product is overly optimistic." He reiterates an Underweight rating on the shares with a $10 price target. Valeant closed yesterday up 26c to $9.85.
04/21/17
WELS
04/21/17
NO CHANGE
WELS
Wells Fargo's Maris cuts Valeant price target range to $7-$9
Wells Fargo analyst David Maris cut his price target range for Valeant Pharmaceuticals to $7-$9 from $10-$13 and keeps an Underperform rating on the name. The drug maker closed yesterday down 14c to $8.88. Valeant shares are not worth the risk, Maris tells investors in a research note. He believes the company will not generate enough free cash flow between now and 2023 to pay its debt maturities. While Valeant's earnings may exceed near-term consensus estimates, investors have better opportunities elsewhere, Maris contends.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$243.60

2.27 (0.94%)

, SPX

S&P 500

15:23
06/28/17
06/28
15:23
06/28/17
15:23
General news
Senate Intelligence Committee to receive Comey memos, Politico says »

Senate Intelligence…

SPY

SPDR S&P 500 ETF Trust

$243.60

2.27 (0.94%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
06/28/17
06/28
15:17
06/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
06/28/17
06/28
15:16
06/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLCO

Melco Resorts & Entertainment

$22.71

-0.29 (-1.26%)

15:10
06/28/17
06/28
15:10
06/28/17
15:10
Options
Melco Resorts with a bullish short-term option play »

Melco Resorts with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/28/17
06/28
15:05
06/28/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

, BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

15:02
06/28/17
06/28
15:02
06/28/17
15:02
Periodicals
Breaking Periodicals news story on Siemens, Bombardier »

Siemens, Bombardier…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

T

AT&T

$37.89

0.186 (0.49%)

15:00
06/28/17
06/28
15:00
06/28/17
15:00
Options
AT&T attracts downside put buyers »

AT&T attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POT

Potash

$16.34

-0.015 (-0.09%)

14:55
06/28/17
06/28
14:55
06/28/17
14:55
Options
Potash put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

, NKTR

Nektar

$18.82

-0.915 (-4.64%)

14:46
06/28/17
06/28
14:46
06/28/17
14:46
Hot Stocks
Before the Move: Watch Cara Therapeutics into osteoarthritis pain results »

Cara Therapeutics (CARA)…

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

NKTR

Nektar

$18.82

-0.915 (-4.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

NRG

NRG Energy

$17.41

0.2001 (1.16%)

14:45
06/28/17
06/28
14:45
06/28/17
14:45
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$20.36

-0.37 (-1.78%)

14:43
06/28/17
06/28
14:43
06/28/17
14:43
Hot Stocks
Golden Entertainment announces approval for Illinois gaming terminal license »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

Labarge

$54.33

-0.085 (-0.16%)

14:30
06/28/17
06/28
14:30
06/28/17
14:30
Options
6X average daily volume in L Brands driven by a three-way spread »

6X average daily volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENX

Fenix Parts

$1.57

0.08 (5.37%)

14:29
06/28/17
06/28
14:29
06/28/17
14:29
Hot Stocks
Fenix Parts plunges after Nasdaq delisting notice »

Shares of microcap Fenix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:28
06/28/17
06/28
14:28
06/28/17
14:28
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$3.45

0.05 (1.47%)

14:25
06/28/17
06/28
14:25
06/28/17
14:25
Conference/Events
KemPharm to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:24
06/28/17
06/28
14:24
06/28/17
14:24
Earnings
Hecla Mining sees Q2 revenue of $127M-$137M, consensus $145.85M »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:21
06/28/17
06/28
14:21
06/28/17
14:21
Hot Stocks
Hecla Mining to offer $500M of senior notes »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVA

Sinovac Biotech

$6.34

-0.07 (-1.09%)

14:20
06/28/17
06/28
14:20
06/28/17
14:20
Hot Stocks
Sinobioway Consortium confirms Sinovac Biotech offer raised to $8 per share »

Shandong Sinobioway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/28/17
06/28
14:17
06/28/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/28/17
06/28
14:16
06/28/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$138.03

-2.55 (-1.81%)

14:10
06/28/17
06/28
14:10
06/28/17
14:10
Options
Defensive option play in the PowerShares QQQ »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGX

Argan

$62.40

0.9 (1.46%)

14:08
06/28/17
06/28
14:08
06/28/17
14:08
Initiation
Argan initiated  »

Argan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.24

0.07 (1.35%)

14:05
06/28/17
06/28
14:05
06/28/17
14:05
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
06/28/17
06/28
14:05
06/28/17
14:05
General news
U.S. equities are extending their bull run »

U.S. equities are…

14:00
06/28/17
06/28
14:00
06/28/17
14:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.